| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/11/2010 | US20100035875 Triazolopyridine jak inhibitor compounds and methods |
| 02/11/2010 | US20100035872 Pde10 inhibitors and related compositions and methods |
| 02/11/2010 | US20100035870 Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds |
| 02/11/2010 | US20100035847 Genes for biosynthesis of tetracycline compounds and uses thereof |
| 02/11/2010 | US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 02/11/2010 | US20100035825 compositions and methods to suppress the activation and/or proliferation of mesenchymally derived cells, as well as cells with abnormal growth characteristics; inhibit or eliminate fibrosis; cancer |
| 02/11/2010 | US20100035824 Synergistic Pharmaceutical Composition |
| 02/11/2010 | US20100035814 N-Terminal Pegylated Prolactin Receptor Molecules |
| 02/11/2010 | US20100035807 Composition and method for treatment of tumors |
| 02/11/2010 | US20100035802 Particular short-chain peptide cancer drug and its treatment |
| 02/11/2010 | US20100035799 Method for the synthesis of anthracycline-peptide conjugates |
| 02/11/2010 | US20100034899 Use of one or more of the elements from the group yttrium, neodymium and zirconium, and pharmaceutical compositions which contain those elements |
| 02/11/2010 | US20100034896 Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs |
| 02/11/2010 | US20100034886 Polyglutamic Acids Functionalised by Histidine Derivatives and Hydrophobic Groups and the Uses Thereof, in Particular for Therapeutic Purposes |
| 02/11/2010 | US20100034874 Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome |
| 02/11/2010 | US20100034842 Compositions Employing Alternative Reading Frame Polypeptides for the Treatment of Cancer and Infectious Disease |
| 02/11/2010 | US20100034837 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| 02/11/2010 | US20100034828 Method of Increasing Radiation Sensitivity by Inhibition of Beta One Integrin |
| 02/11/2010 | US20100034825 Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| 02/11/2010 | US20100034823 Crystalline anti-hTNFalpha antibodies |
| 02/11/2010 | US20100034821 Genetic variations associated with tumors |
| 02/11/2010 | US20100034813 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 02/11/2010 | US20100034776 Replication-competent anti-cancer vectors |
| 02/11/2010 | US20100034762 Novel enrichment methods for gallic acid esters including 1-O-galloy1-bata-D-glucose and mucic acid gallates medicaments, therapeutic applications and methods of treatment thereof |
| 02/11/2010 | US20100034737 Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use |
| 02/11/2010 | US20100034736 Identification of cancer stem cells using genetic markers |
| 02/11/2010 | CA2735710A1 Sting (stimulator of interferon genes), a regulator of innate immune responses |
| 02/11/2010 | CA2733506A1 Biological applications of steroid binding domains |
| 02/11/2010 | CA2733461A1 Methods of predicting cancer lethality using replikin counts |
| 02/11/2010 | CA2733458A1 Lipid compounds for suppression of tumorigenesis |
| 02/11/2010 | CA2733223A1 Pharmaceutical composition for treatment and prevention of cancers |
| 02/11/2010 | CA2733203A1 Use of mtor inhibitors to enhance t cell immune responses |
| 02/11/2010 | CA2733159A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| 02/11/2010 | CA2733153A1 Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| 02/11/2010 | CA2732950A1 Imidazopyridin-2-one derivatives |
| 02/11/2010 | CA2732850A1 Pharmaceutical uses of lanosta-8,24-dien-3-ols |
| 02/11/2010 | CA2732828A1 Novel phenylamino isonicotinamide compounds |
| 02/11/2010 | CA2732283A1 Immunity-inducing agent |
| 02/11/2010 | CA2732101A1 Aurora kinase modulators and methods of use |
| 02/11/2010 | CA2731368A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| 02/11/2010 | CA2730715A1 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| 02/11/2010 | CA2730448A1 Inhibitors of iap |
| 02/10/2010 | EP2151454A2 Platelet-derived growth factor D, DNA coding therefor, and uses thereof |
| 02/10/2010 | EP2151448A1 Glycosylate derivatives of mithramycin, method of preparation and uses thereof |
| 02/10/2010 | EP2151245A1 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 02/10/2010 | EP2151244A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/10/2010 | EP2150618A1 Il-12 immunotherapy for cancer |
| 02/10/2010 | EP2150613A1 Mutant reoviruses and methods of making and using |
| 02/10/2010 | EP2150553A1 Condensed heterocyclic compounds as inhibitors of protein kinases |
| 02/10/2010 | EP2150551A1 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors |
| 02/10/2010 | EP2150546A2 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| 02/10/2010 | EP2150539A1 Pyridazinone derivatives |
| 02/10/2010 | EP2150527A2 Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
| 02/10/2010 | EP2150278A1 Novel photosensitizer based on polymer derivatives-photosensitizer conjugates for photodynamic therapy |
| 02/10/2010 | EP2150276A1 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide |
| 02/10/2010 | EP2150270A2 Methods and compositions for the treatment of cancer |
| 02/10/2010 | EP2150263A1 Plant extract and its therapeutic use |
| 02/10/2010 | EP2150252A1 Raf inhibitors for the treatment of thyroid cancer |
| 02/10/2010 | EP1618102B1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 02/10/2010 | EP1490365B1 Azaindoles as inhibitors of c-jun n-terminal kinases |
| 02/10/2010 | EP1404659B1 4-aryl quinols and analogs thereof as therapeutic agents |
| 02/10/2010 | EP1383924B1 Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof |
| 02/10/2010 | EP1354896B1 Monoclonal antibody directed against the human bst2 antigen |
| 02/10/2010 | EP0910655B1 Vaccines for treatment of lymphoma and leukemia |
| 02/10/2010 | CN101643789A RNA interference mediating small RNA molecules |
| 02/10/2010 | CN101643732A A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 02/10/2010 | CN101642458A Use of cyclopamine in the treatment of psoriasis and other skin disorders |
| 02/10/2010 | CN100588662C Cancerous disease modifying antibodies |
| 02/10/2010 | CN100588649C Method for producing condensed imidazole compound, reformatsky reagent having stable form and production thereof |
| 02/10/2010 | CN100588647C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/10/2010 | CN100588398C Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances |
| 02/09/2010 | US7659412 Benzofuran derivatives useful for treating hyper-proliferative disorders |
| 02/09/2010 | US7659391 Method for the in vitro synthesis of short double stranded RNAs |
| 02/09/2010 | US7659385 Polynucleotides encoding molecules designated LDCAM |
| 02/09/2010 | US7659377 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
| 02/09/2010 | US7659370 Nervous system protein for use in treatment and prevention of nervous system and seizure disorders |
| 02/09/2010 | US7659367 Contains insulin-like growth factor-I, insulin-like growth factor binding protein 3 and integrin-binding domain of vitronectin ; wound healing; surgical implant, prosthesis, scaffold, wound or burn dressing |
| 02/09/2010 | US7659303 Reduce tumor necrosis factor; phosphodiesterase inhibitor; antiinflammatory agents; anticancer agents; antidepressants; skin diosrders |
| 02/09/2010 | US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
| 02/09/2010 | US7659293 α-Amino-N-hydroxy-acetamide derivatives |
| 02/09/2010 | US7659279 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer |
| 02/09/2010 | US7659278 Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases |
| 02/09/2010 | US7659267 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding |
| 02/09/2010 | US7659257 Medicament for treating lung cancer |
| 02/09/2010 | US7659241 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 02/09/2010 | US7659117 Immunostimulatory fusion proteins comprising polypeptide antigen for generating protective DC-induced T-cell-mediated immune responses; metastatic cancers |
| 02/09/2010 | US7659071 Using cell-mediated immune response to e6 and e7 peptides as diagnostic/prognostic indication of recurrence and/or development of cervical intraepithelial neoplasia (CIN) |
| 02/09/2010 | US7658931 Genetically modified cholera toxin (CT-CRM) comprising reduced toxicity and enhanced immunological response for use in preparation of vaccines against parasitic infection |
| 02/09/2010 | US7658923 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26 |
| 02/09/2010 | CA2466372C Non-human transgenic mammals used as models for human pathologies originating from stem cells |
| 02/09/2010 | CA2440760C Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 02/09/2010 | CA2439593C Heterocyclic compounds for aging-related and diabetic vascular complications |
| 02/09/2010 | CA2413061C Serine protease inhibitors |
| 02/09/2010 | CA2404945C Taci as an anti-tumor agent |
| 02/09/2010 | CA2403756C Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| 02/09/2010 | CA2363934C Oligomers substituted by phosphite ester, phosphonic acid,or carbaborane functions and the corresponding pna monomers |
| 02/09/2010 | CA2353612C Boron neutron capture therapy using pre-targeting methods |
| 02/09/2010 | CA2338546C Particle-forming compositions containing fused pyrrolocarbazoles |
| 02/09/2010 | CA2315646C Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| 02/09/2010 | CA2294274C Compositions and methods for reversibly increasing permeability of biomembranes |